Results 181 to 190 of about 32,129 (220)
Novel cyp51A mutation profile in Aspergillus fumigatus from a patient with systemic lupus erythematosus and limited systemic sclerosis: first clinical case of acquired azole-resistance in Colombia. [PDF]
BMC Infect DisMorales-Pertuz C +6 more
europepmc +1 more source
Shifting Epidemiology and Antifungal Susceptibility Patterns of Clinical Fungal Isolates in an Intensive Care Unit (ICU) from Bucharest, Romania: A Retrospective Observational Study. [PDF]
Antibiotics (Basel)Solomon MP +6 more
europepmc +1 more source
Adverse Reactions to Voriconazole
Clinical Infectious Diseases, 2004 Voriconazole is a new antifungal agent effective in the treatment of invasive aspergillosis. Interpatient variation in plasma concentrations is considerable - more than 100-fold.
David W Denning, , Brian G Keevil
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Clinical Therapeutics, 2003
Reports of resistance and intolerance to currently available antifungal agents are increasing. Voriconazole is a broad-spectrum azole antifungal agent structurally derived from fluconazole. It is indicated for the treatment of invasive aspergillosis and serious fungal infections caused by Scedosporium apiospermum and Fusarium species in patients who ...
LilyAnn, Jeu +3 more
openaire +2 more sources
Reports of resistance and intolerance to currently available antifungal agents are increasing. Voriconazole is a broad-spectrum azole antifungal agent structurally derived from fluconazole. It is indicated for the treatment of invasive aspergillosis and serious fungal infections caused by Scedosporium apiospermum and Fusarium species in patients who ...
LilyAnn, Jeu +3 more
openaire +2 more sources
Pharmacoeconomics of voriconazole
Expert Opinion on Pharmacotherapy, 2010The recent increase in the use of antineoplastic and immune suppressive agents and the use of broad-spectrum antibiotics, prosthetic interventions, organ transplants and more aggressive surgery have been related to a greater prevalence of invasive fungal infections (IFI).
Carlos, Rubio-Terrés, Santiago, Grau
openaire +2 more sources
Hospital Pharmacy, 2002
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J Cada +2 more
openaire +1 more source
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J Cada +2 more
openaire +1 more source
Voriconazole therapy in children with cystic fibrosis
Journal of Cystic Fibrosis, 2005 BackgroundThere is increasing evidence for the efficacy of the antifungal voriconazole, particularly in immunosuppression. We describe our experience of using voriconazole in children with CF.MethodsWe performed a retrospective case note review of ...
Tom Hilliard +2 more
exaly +2 more sources